TNFRSF9 and neoplasm: In the present study, we have reported the generation, characterization, anti‐tumor efficacy, preliminary pharmacokinetics, and toxicology studies of a novel fully human anti‐CD137 antibody (named PE0116), which is derived from a hybridoma platform based on transgenic H2L2 mice immunized by hCD137 ECD‐hFc protein.